NesbuvirNS5B polymerase inhibitor CAS# 691852-58-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 691852-58-1 | SDF | Download SDF |
PubChem ID | 11561383 | Appearance | Powder |
Formula | C22H23FN2O5S | M.Wt | 446.49 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | HCV-796 | ||
Solubility | DMSO : ≥ 50 mg/mL (111.98 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 5-cyclopropyl-2-(4-fluorophenyl)-6-[2-hydroxyethyl(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide | ||
SMILES | CNC(=O)C1=C(OC2=CC(=C(C=C21)C3CC3)N(CCO)S(=O)(=O)C)C4=CC=C(C=C4)F | ||
Standard InChIKey | WTDWVLJJJOTABN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H23FN2O5S/c1-24-22(27)20-17-11-16(13-3-4-13)18(25(9-10-26)31(2,28)29)12-19(17)30-21(20)14-5-7-15(23)8-6-14/h5-8,11-13,26H,3-4,9-10H2,1-2H3,(H,24,27) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Nesbuvir is a selective inhibitor of HCV NS5B RNA-dependent RNA polymerase. | |||||
Targets | HCV NS5B RNA-dependent RNA polymerase |
Nesbuvir Dilution Calculator
Nesbuvir Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2397 mL | 11.1985 mL | 22.3969 mL | 44.7938 mL | 55.9923 mL |
5 mM | 0.4479 mL | 2.2397 mL | 4.4794 mL | 8.9588 mL | 11.1985 mL |
10 mM | 0.224 mL | 1.1198 mL | 2.2397 mL | 4.4794 mL | 5.5992 mL |
50 mM | 0.0448 mL | 0.224 mL | 0.4479 mL | 0.8959 mL | 1.1198 mL |
100 mM | 0.0224 mL | 0.112 mL | 0.224 mL | 0.4479 mL | 0.5599 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Nesbuvir is a novel selective inhibitor of nonstructural protein 5B (NS5B) polymerase with IC50 value of 5 nM [1].
NS5B (nonstructural protein 5B) is a viral protein found in HCV and plays an important role in HCV RNA replicate by using the viral positive RNA strand as its template and catalyzing the polymerization of rNTP during RNA replication. As the principal catalytic enzyme for HCV replication, NS5B is a viable target for HCV-RNA replication and used as a target for HCV therapy [2] [3].
Nesbuvir is a selective NS5B polymerase inhibitor and has a different selectivity with the reported ALK inhibitor crizotinib. When tested with Huh7.5 cell line, nesbuvir showed the highest selectivity for NS5B and mutations reduced the cells susceptibility [1]. In Clone A cells derived from Huh-7 cells containing approximately 1,000 genome copies of HCV genotype 1b replicon per cell, nesbuvir treatment with the concentration of 0.1 and 1 μM for 16-day reduced about 3.6 log10 and 4.2 log10 HCV RNA levels, respectively [2].
In the chimeric mouse model, nesbuvir treatment resulted in a 2.02 +/- 0.55 log reduction in HCV titer, whereas in combination with interferon using a suboptimal dose of 30 mg/kg three times per day showed a 2.44 log reduction and were better than interferon treatment only [4].
References:
[1]. Flint, M., et al., Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother, 2009. 53(2): p. 401-11.
[2]. Howe, A.Y., et al., Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother, 2008. 52(9): p. 3327-38.
[3]. Meshram, R.J. and R.N. Gacche, Effective epitope identification employing phylogenetic, mutational variability, sequence entropy, and correlated mutation analysis targeting NS5B protein of hepatitis C virus: from bioinformatics to therapeutics. J Mol Recognit, 2015.
[4]. Kneteman, N.M., et al., HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology, 2009. 49(3): p. 745-52.
- (2S,3R,E)-2-Amino-4-heptadecene-1,3-diol
Catalog No.:BCN1765
CAS No.:6918-48-5
- Gomisin N
Catalog No.:BCN2271
CAS No.:69176-52-9
- Tigloylgomisin P
Catalog No.:BCN6926
CAS No.:69176-51-8
- Malic acid
Catalog No.:BCN2699
CAS No.:6915-15-7
- Aromadendrin 7-O-rhamnoside
Catalog No.:BCN8114
CAS No.:69135-41-7
- Fiacitabine
Catalog No.:BCC1574
CAS No.:69123-90-6
- Moracin D
Catalog No.:BCN4255
CAS No.:69120-07-6
- Moracin C
Catalog No.:BCN4254
CAS No.:69120-06-5
- 16-Hydroxy-8(17),13-labdadien-15,16-olid-19-oic acid
Catalog No.:BCN1378
CAS No.:691009-85-5
- Acetoxyisovalerylalkannin
Catalog No.:BCN3007
CAS No.:69091-17-4
- Demanyl phosphate
Catalog No.:BCN1796
CAS No.:6909-62-2
- 2-Caren-10-ol
Catalog No.:BCN4253
CAS No.:6909-19-9
- (±)-Hexanoylcarnitine chloride
Catalog No.:BCC6680
CAS No.:6920-35-0
- 2'-Hydroxy-4'-methylacetophenone
Catalog No.:BCN7751
CAS No.:6921-64-8
- Osthol hydrate
Catalog No.:BCN1377
CAS No.:69219-24-5
- Pinoresinol 4-O-beta-D-glucopyranoside
Catalog No.:BCN1376
CAS No.:69251-96-3
- 1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid
Catalog No.:BCN7205
CAS No.:69251-99-6
- N-Benzylcinchonidinium chloride
Catalog No.:BCC9094
CAS No.:69257-04-1
- Harpagide
Catalog No.:BCN4996
CAS No.:6926-08-5
- 8-O-Acetylharpagide
Catalog No.:BCN4256
CAS No.:6926-14-3
- 3-beta-O-(cis-p-Coumaroyl)maslinic acid
Catalog No.:BCN1375
CAS No.:69297-40-1
- 12-Aminolauric acid
Catalog No.:BCC8436
CAS No.:693-57-2
- (R)-baclofen
Catalog No.:BCC4503
CAS No.:69308-37-8
- H-Ile-OtBu.HCl
Catalog No.:BCC2965
CAS No.:69320-89-4
Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.[Pubmed:25246395]
Antimicrob Agents Chemother. 2014 Dec;58(12):7215-24.
Direct-acting antivirals (DAAs) targeting proteins encoded by the hepatitis C virus (HCV) genome have great potential for the treatment of HCV infections. However, the efficacy of DAAs designed to target genotype 1 (G1) HCV against non-G1 viruses has not been characterized fully. In this study, we investigated the inhibitory activities of nonnucleoside inhibitors (NNIs) against the HCV RNA-dependent RNA polymerase (RdRp). We examined the ability of six NNIs to inhibit G1b, G2a, and G3a subgenomic replicons in cell culture, as well as in vitro transcription by G1b and G3a recombinant RdRps. Of the six G1 NNIs, only the palm II binder Nesbuvir demonstrated activity against G1, G2, and G3 HCV, in both replicon and recombinant enzyme models. The thumb I binder JTK-109 also inhibited G1b and G3a replicons and recombinant enzymes but was 41-fold less active against the G2a replicon. The four other NNIs, which included a palm I binder (setrobuvir), two thumb II binders (lomibuvir and filibuvir), and a palm beta-hairpin binder (tegobuvir), all showed at least 40-fold decreases in potency against G2a and G3a replicons and the G3a enzyme. This antiviral resistance was largely conferred by naturally occurring amino acid residues in the G2a and G3a RdRps that are associated with G1 resistance. Lomibuvir and filibuvir (thumb II binders) inhibited primer-dependent but not de novo activity of the G1b polymerase. Surprisingly, these compounds instead specifically enhanced the de novo activity at concentrations of >/= 100 nM. These findings highlight a potential differential mode of RdRp inhibition for HCV NNIs, depending on their prospective binding pockets, and also demonstrate a surprising enhancement of de novo activity for thumb RdRp binders. These results also provide a better understanding of the antiviral coverage for these polymerase inhibitors, which will likely be used in future combinational interferon-free therapies.
Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.[Pubmed:28621755]
Viruses. 2017 Jun 16;9(6). pii: v9060151.
Allosteric inhibitors of hepatitis C virus (HCV) non-structural protein 5B (NS5B) polymerase are effective for treatment of genotype 1, although their mode of action and potential to inhibit other isolates and genotypes are not well established. We have used biophysical techniques and a novel biosensor-based real-time polymerase assay to investigate the mode-of-action and selectivity of four inhibitors against enzyme from genotypes 1b (BK and Con1) and 3a. Two thumb inhibitors (lomibuvir and filibuvir) interacted with all three NS5B variants, although the affinities for the 3a enzyme were low. Of the two tested palm inhibitors (dasabuvir and Nesbuvir), only dasabuvir interacted with the 1b variant, and Nesbuvir interacted with NS5B 3a. Lomibuvir, filibuvir and dasabuvir stabilized the structure of the two 1b variants, but not the 3a enzyme. The thumb compounds interfered with the interaction between the enzyme and RNA and blocked the transition from initiation to elongation. The two allosteric inhibitor types have different inhibition mechanisms. Sequence and structure analysis revealed differences in the binding sites for 1b and 3a variants, explaining the poor effect against genotype 3a NS5B. The indirect mode-of-action needs to be considered when designing allosteric compounds. The current approach provides an efficient strategy for identifying and optimizing allosteric inhibitors targeting HCV genotype 3a.